<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01896739</url>
  </required_header>
  <id_info>
    <org_study_id>LG-VACL004</org_study_id>
    <nct_id>NCT01896739</nct_id>
  </id_info>
  <brief_title>A Phase III Study to Assess the Immunogenicity and Safety of Eutravac (DTap-HB Combined Vaccine) With DTaP and Hepatitis B Vaccines in Healthy Infants</brief_title>
  <official_title>A Multicentre, Comparative, Open-label, Randomized, Phase III Study to Assess the Immunogenicity and Safety of EutravacTMinj (DTaP-HB Combined Vaccine) Administered at 2,4, 6 Months of Age Compared With DTaP Vaccine at 2, 4, 6 Months of Age Combined Administered Monovalent Hepatitis B Vaccine Administered at Birth, 1, 6 Months of Age in Healthy Infants.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate and compare the immunogenicity of Eutravac (Diphtheria-Tetanus-acellular
      Pertussis [DTaP] Hepatitis B [HB] combined) vaccine with separate but simultaneous
      administrations of DTaP and HB vaccine each administered to healthy infants, as measured by
      seroprotection/vaccine response rates 4-8 weeks post-final immunisation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroprotection rate</measure>
    <time_frame>After final immunisation at 4-8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">289</enrollment>
  <condition>Healthy Infants</condition>
  <arm_group>
    <arm_group_label>Experimental group with 0-2-4-6 schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HB at 0, Eutravac at 2-4-6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active comparator group with 0-2-4-6 schedule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Separate injection of DTaP and HB at 2-4-6 (for DTaP) and 0-1-6 (HB)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group with 2-4-6 schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eutravac at 2-4-6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active comparator group with 2-4-6 schedule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Separate injection of DTaP and HB at 2-4-6 (for DTaP) and 0-1-6 (HB)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Eutravac</intervention_name>
    <arm_group_label>Experimental group with 0-2-4-6 schedule</arm_group_label>
    <arm_group_label>Active comparator group with 0-2-4-6 schedule</arm_group_label>
    <arm_group_label>Experimental group with 2-4-6 schedule</arm_group_label>
    <arm_group_label>Active comparator group with 2-4-6 schedule</arm_group_label>
    <other_name>LG DTaP Vaccine Inj. (DTaP)</other_name>
    <other_name>Euvax B (Hepatitis B)</other_name>
    <other_name>Hepavax (Hepatitis B)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Were healthy, male or female infants born at full term pregnancy (≥37 weeks) with a
             birth weight ≥2.5 kg to mothers with a negative HBsAg serology, documented prior to
             giving birth as per routine, site-specific ante-natal care procedures.

          -  Signed parental or legally acceptable representative's informed consent was obtained

        Exclusion Criteria:

          -  Evidence of an acute febrile illness with axillary temperature ≥37.5℃ on the day of
             the vaccination. Infants with symptoms of minor illness eg, mild gastroenteritis, mild
             upper respiratory tract infection and who did not have a temperature ≥37.5℃ on the day
             of the vaccination could be included at the Investigator's discretion

          -  History of diphtheria, tetanus, pertussis or hepatitis B disease

          -  History of any vaccine-related hypersensitivity or anaphylactic reaction after
             previous administration of Euvax B
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Catholic University of Korea ST. Vincent's Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <zip>442-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daejeon St. Mary's Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>301-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeju National University Hospital</name>
      <address>
        <city>Jeju</city>
        <zip>690-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>130-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cha Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>135-913</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea Cancer Center Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>139-709</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2013</study_first_submitted>
  <study_first_submitted_qc>July 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2013</study_first_posted>
  <last_update_submitted>July 8, 2013</last_update_submitted>
  <last_update_submitted_qc>July 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy infants with over than 37 weeks gestation periods.</keyword>
  <keyword>over than 2.5Kg at at birth weight.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

